NOVN.CH

91.26

+1.16%↑

NOVN.CH

91.26

+1.16%↑

NOVN.CH

91.26

+1.16%↑

NOVN.CH

91.26

+1.16%↑

NOVN.CH

91.26

+1.16%↑

Search

Lonza Group AG

Geschlossen

BrancheGesundheitswesen

571.6 0.99

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

566

Max

573.6

Schlüsselkennzahlen

By Trading Economics

Einkommen

-22M

307M

Verkäufe

460M

3.5B

KGV

Branchendurchschnitt

64.697

56.602

EPS

4.31

Dividendenrendite

0.69

Gewinnspanne

8.729

Angestellte

17,995

EBITDA

-60M

764M

Empfehlungen

By TipRanks

Empfehlungen

Starkes Kaufsignal

12-Monats-Prognose

+13.04% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

0.69%

2.45%

Nächstes Ergebnis

23. Juli 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-561M

42B

Vorheriger Eröffnungskurs

570.61

Vorheriger Schlusskurs

571.6

Nachrichtenstimmung

By Acuity

14%

86%

14 / 382 Ranking in Healthcare

Lonza Group AG Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

9. Mai 2025, 05:18 UTC

Ergebnisse

Lonza Doesn't Expect Tariff Hit, Backs Outlook for CDMO Business

18. Feb. 2025, 12:22 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Picks BofA, Centerview Partners for Capsules Unit Sale, Bloomberg Law Says, Citing Sources

12. Dez. 2024, 09:26 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Streamlines Business With Capsules Unit Exit -- 2nd Update

12. Dez. 2024, 07:45 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Streamlines Business With Capsules Unit Exit -- Update

12. Dez. 2024, 06:52 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Streamlines Organizational Structure

9. Mai 2025, 14:45 UTC

Market Talk

Big Pharma's U.S. Expansion Will Take Years to Materialize, Lonza CFO Says -- Market Talk

9. Mai 2025, 14:42 UTC

Market Talk

Big Pharma U.S. Investment Plans Might Not Bring Extra Spending, Lonza CFO Says -- Market Talk

8. Apr. 2025, 07:34 UTC

Market Talk

Lonza Well Protected From Tariffs -- Market Talk

29. Jan. 2025, 08:11 UTC

Market Talk
Ergebnisse

Lonza's Outlook Looks Positive -- Market Talk

29. Jan. 2025, 07:22 UTC

Market Talk
Ergebnisse

Lonza Had a Mixed Year Across Divisions -- Market Talk

29. Jan. 2025, 07:11 UTC

Market Talk
Ergebnisse

Lonza's Results Don't Contain Any Surprises -- Market Talk

29. Jan. 2025, 06:26 UTC

Top News
Ergebnisse

Lonza Posts Lower Sales, Earnings But Expects Capsules Business Rebound This Year

16. Jan. 2025, 10:32 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Lonza's Midterm Outlook Is Positive -- Market Talk

16. Dez. 2024, 22:03 UTC

Top News

Novo's New Deal May End Wegovy Shortages. It Could Reshape the Pharma Industry Along the Way. -- Barrons.com

13. Dez. 2024, 08:07 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Lonza Unlikely to Pursue Large Acquisitions -- Market Talk

12. Dez. 2024, 08:51 UTC

Market Talk
Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Lonza's Exit of Capsules Business Is a Positive Move -- Market Talk

12. Dez. 2024, 08:02 UTC

Market Talk
Akquisitionen, Fusionen, Übernahmen

Lonza's Divestiture of Capsules Division Shouldn't Surprise -- Market Talk

12. Dez. 2024, 05:59 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Targets Dividend Pay-Out Ratio Between 35%-45%

12. Dez. 2024, 05:59 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Confirms Div Policy; to Maintain or Increase Div Per Shr Year-on-Year

12. Dez. 2024, 05:58 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Sees Low-To-Mid Single-Digit CER Sales Growth Beyond 2025

12. Dez. 2024, 05:58 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Sees CHI Core Ebitda Margin in the Mid-Twenties for 2025

12. Dez. 2024, 05:58 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Sees Gradual Return to Previous Core Ebitda Margin Beyond 2025

12. Dez. 2024, 05:57 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Sees Low-To-Mid Single-Digit CHI Sales Growth for 2025

12. Dez. 2024, 05:55 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Sees Core 2025 Ebitda Growth Ahead of Sales Growth

12. Dez. 2024, 05:54 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza CHF 2025 Sales From Vacaville, Core Ebitda Margin Approaching 30%

12. Dez. 2024, 05:54 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza CDMO 2025 Outlook Approaching 20% Sales Growth in CER

12. Dez. 2024, 05:53 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Sees 2024 Core Ebitda Margin of 27-29%

12. Dez. 2024, 05:53 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Sees Flat 2024 CER Sales Growth

12. Dez. 2024, 05:52 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza Backs 2024 View

12. Dez. 2024, 05:52 UTC

Akquisitionen, Fusionen, Übernahmen

Lonza: CDMO Business to Be Structured Into Three New Business Platforms

Peer-Vergleich

Kursveränderung

Lonza Group AG Prognose

Kursziel

By TipRanks

13.04% Vorteil

12-Monats-Prognose

Durchschnitt 645 CHF  13.04%

Hoch 670 CHF

Tief 630 CHF

Basierend auf 4 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Lonza Group AG – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

4 ratings

3

Buy

1

Halten

0

Sell

Stimmung

By Acuity

14 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Sehr starke bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Lonza Group AG

Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia, New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. This segment also supports customers across various aspects of design, development, and manufacturing, including particle engineering and drug product packaging. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies; offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. This segment also provides Cocoon platform, a closed automated system for patient-scale cell therapy manufacturing; and specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. Lonza Group AG was incorporated in 1897 and is headquartered in Basel, Switzerland.